Grant Bogle

Grant Bogle

Director/Board Member at NUVALENT, INC.

Net worth: 1 M $ as of 31/05/2026

68 year
Health Technology
Health Services
Consumer Services

Profile

Grant C.
Bogle
is currently Director at Gladius Therapeutics, Inc., Director at Myrobalan Therapeutics, Inc., Director at American School for the Deaf, and Independent Director at Nuvalent, Inc. since 2024.
Former roles include President, Chief Executive Officer, CFO & Director at Epizyme, Inc. from 2021 to 2022; Principal at EIDP, Inc., Roche Pharmaceuticals, Inc., Abbott India Ltd., and American Hospital Supply Corp.; Senior Vice President-Sales & Marketing at Millennium Pharmaceuticals, Inc.; EVP-Strategy & Emerging Businesses at US Oncology, Inc. from 2010 to 2011; Executive VP-Integrated Oncology Solutions at US Oncology Holdings, Inc.; Chief Commercial Officer & Senior Vice President at Tesaro, Inc. from 2015 to 2019; and Senior VP-Pharmaceutical & Biotech Solutions at McKesson Specialty Health, Inc. Education includes an MBA from The Trustees of Columbia University in The City of New York and undergraduate studies at Dartmouth College.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
16/06/2026 9,291 ( 0.01% ) 1 M $ 31/05/2026

Grant Bogle active positions

CompaniesPositionStart
NUVALENT, INC. Director/Board Member 09/12/2024
Director/Board Member -
Director/Board Member -
Director/Board Member -

Former positions of Grant Bogle

CompaniesPositionEnd
TESARO INC Corporate Officer/Principal 22/01/2019
EPIZYME, INC. Chief Executive Officer -
Corporate Officer/Principal -
Corporate Officer/Principal -
Corporate Officer/Principal -
See the detail of Grant Bogle's experience

Training of Grant Bogle

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

13

1st degree connections

16

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies16

Process Industries

Health Technology

Health Services

Commercial Services

Health Services

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Consumer Services

Health Services

Health Technology

Health Technology

Health Technology